6.78
前日終値:
$7.26
開ける:
$7.26
24時間の取引高:
1.40M
Relative Volume:
1.76
時価総額:
$280.67M
収益:
$134.48M
当期純損益:
$-38.94M
株価収益率:
-7.1114
EPS:
-0.9534
ネットキャッシュフロー:
$-19.34M
1週間 パフォーマンス:
-0.44%
1か月 パフォーマンス:
-3.42%
6か月 パフォーマンス:
-21.25%
1年 パフォーマンス:
-51.40%
Rxsight Inc Stock (RXST) Company Profile
Compare RXST vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
RXST
Rxsight Inc
|
6.78 | 300.54M | 134.48M | -38.94M | -19.34M | -0.9534 |
|
ABT
Abbott Laboratories
|
86.30 | 151.83B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
292.33 | 113.08B | 25.27B | 3.34B | 4.57B | 8.6358 |
|
MDT
Medtronic Plc
|
77.60 | 99.87B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
56.00 | 83.21B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
83.20 | 47.80B | 6.30B | 1.07B | 1.34B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-30 | 開始されました | William Blair | Mkt Perform |
| 2025-07-15 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | ダウングレード | Jefferies | Buy → Hold |
| 2025-07-09 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-07-09 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-07-09 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | 開始されました | Piper Sandler | Neutral |
| 2025-04-09 | ダウングレード | UBS | Buy → Neutral |
| 2025-04-04 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2025-04-03 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-12-20 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-11 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | 開始されました | UBS | Buy |
| 2024-10-29 | 開始されました | Jefferies | Buy |
| 2024-08-20 | 繰り返されました | Needham | Buy |
| 2024-08-06 | 繰り返されました | Needham | Buy |
| 2024-05-07 | 繰り返されました | BTIG Research | Buy |
| 2023-12-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | 開始されました | Stifel | Buy |
| 2023-12-04 | 開始されました | Morgan Stanley | Overweight |
| 2023-04-13 | 開始されました | Oppenheimer | Outperform |
| 2022-12-12 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | 開始されました | Needham | Buy |
すべてを表示
Rxsight Inc (RXST) 最新ニュース
Earnings call transcript: RxSight beats Q1 2026 forecasts, stock dips - Investing.com
RxSight (NASDAQ:RXST) Q1 2026 Results: Revenue Beats but Loss Widens Amid Cautious Market Reaction - ChartMill
RxSight, Inc. (RXST) Tops Q1 EPS by 12c - StreetInsider
RxSight (RXST) Q1 2026 revenue drops 18.5% as net loss nearly doubles - Stock Titan
Eye-lens maker RxSight says sales slowed, but kept 2026 target - Stock Titan
RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook - GlobeNewswire
RxSight (NASDAQ: RXST) posts wider Q1 loss but keeps 2026 sales outlook - Stock Titan
Rxsight Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Behavioral Patterns of RXST and Institutional Flows - Stock Traders Daily
How The RxSight (RXST) Narrative Is Shifting After 2026 Guidance And Target Resets - Yahoo! Finance Canada
RxSight, Inc. to Present at the Bank of America Healthcare Conference - Bluefield Daily Telegraph
Needham Maintains RxSight (RXST) Buy Recommendation - MSN
RxSight (RXST) to Release Earnings on Wednesday - MarketBeat
RxSight (NASDAQ: RXST) sets 2026 virtual meeting on directors, pay and auditor - Stock Titan
[ARS] RxSight, Inc. SEC Filing - Stock Titan
(RXST) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6 - The Manila Times
RXST SEC FilingsRxsight, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
RxSight (RXST) COO exercises stock options, now holding over 79,000 shares - Stock Titan
How The RxSight (RXST) Story Is Shifting With New Guidance And Street Price Targets - Yahoo Finance
RxSight (RXST) Stock: Mid-Year Review (Extends Gains) 2026-04-18Volatility Analysis - Cổng thông tin điện tử tỉnh Lào Cai
RxSight, Inc. (RXST) Stock Analysis: Exploring a 34% Potential Upside Amidst Market Challenges - DirectorsTalk Interviews
Analysts’ Top Healthcare Picks: RxSight (RXST), Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Needham Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $13 - Moomoo
RXST: Premium lens adoption grows as utilization deepens and international expansion accelerates - TradingView
RxSight (RXST) Stock: Valuation Analysis (Steady Decline) 2026-04-15Scalping - Cổng thông tin điện tử tỉnh Lào Cai
Volume Summary: Will RxSight Inc benefit from geopolitical trends2026 Short Interest & Weekly Top Stock Performers List - baoquankhu1.vn
Trend Report: Is RxSight Inc forming a double bottom2026 Key Lessons & Stepwise Trade Signal Guides - baoquankhu1.vn
Retail Surge: Can RxSight Inc deliver consistent EPS growthWeekly Trend Summary & Fast Exit Strategy with Risk Control - baoquankhu1.vn
How (RXST) Movements Inform Risk Allocation Models - Stock Traders Daily
RxSight, Inc. (NASDAQ:RXST) Given Consensus Recommendation of "Reduce" by Analysts - MarketBeat
Gains Report: What is RxSight Incs valuation compared to sector2026 Intraday Action & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Market Moves: Will RxSight Inc stock hit new highs in YEARQuarterly Earnings Report & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Analysis Recap: Will RxSight Inc benefit from geopolitical trendsJobs Report & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Investment Recap: Will RxSight Inc benefit from geopolitical trendsSwing Trade & Stepwise Trade Signal Guides - baoquankhu1.vn
RxSight Inc stock: 300,000 Lens Milestone Signals Growth Potential - AD HOC NEWS
RxSight Reaches 300,000 Light Adjustable Lens Implant Milestone - National Today
RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026 - Sahm
RxSight, Inc. (RXST) stock price, news, quote and history - Yahoo Finance Australia
RxSight reports 300,000 Light Adjustable Lens implants milestone By Investing.com - Investing.com South Africa
RxSight reports 300,000 Light Adjustable Lens implants milestone - Investing.com
RxSight reaches 300,000 Light Adjustable Lens implants since launch - StreetInsider
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against RxSight, Inc. (RXST) And Encourages Shareholders to Reach Out - ACCESS Newswire
RxSight (NASDAQ:RXST) Trading Down 3.7%Time to Sell? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against RxSight, Inc. (RXST) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
2026-04-05 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against RxSight, Inc. (RXST) and Encourages Shareholders to Learn More About the Investigation | NDAQ:RXST | Press Release - Stockhouse
How The Story Is Shifting For RxSight (RXST) On Guidance Leadership And Valuation - Yahoo Finance
RXST PE Ratio & Valuation, Is RXST Overvalued - Intellectia AI
RxSight, Inc. (RXST) Stock Price, News, Quote & History - Yahoo! Finance Canada
RxSight, Inc. (RXST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
RxSight to Participate in Annual Healthcare Conference - National Today
Rxsight Inc (RXST) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):